Shop for inositol and you will see two names, myo-inositol and D-chiro inositol, and one number everywhere: 40:1. Here is myo-inositol vs. D-chiro inositol explained: what each does in your body, where 40:1 comes from, what the research really shows, and how to read a label.
Quick answer: Myo-inositol and D-chiro inositol are two forms of the same molecule that do different jobs. Myo-inositol is the main form in most tissues and in the ovary, where it supports FSH signaling and egg development. D-chiro inositol is made from myo-inositol by an insulin-driven enzyme, mostly in glucose-storing tissues like liver and muscle. The 40:1 ratio mirrors the balance in healthy blood plasma, and small studies suggest it works better than D-chiro-heavy formulas, though the evidence is still early and myo-inositol alone also has research behind it.
Most of the studies below use the older name PCOS; for background, see what the PMOS name change means.
Key takeaways
- Myo-inositol (MI) is the inositol your cells use most. D-chiro inositol (DCI) is a specialized form your body converts from MI.
- Healthy plasma carries roughly 40 parts MI to 1 part DCI. The fluid around a developing egg carries about 100:1.
- More D-chiro is not better. At high doses it may push the ovary toward more androgens and less estrogen, a problem researchers call the D-chiro (or ovarian) paradox.
- The best-known 40:1 trial was small (8 women per group). Myo alone and the 40:1 blend both have supportive studies, and no large trial has settled which is better.
- On a label, check milligrams per serving, capsules or scoops per serving, and whether the ratio really works out to about 40:1.
What Is Myo-Inositol?
Inositol is a sugar-like compound your body makes and also gets from foods like beans, citrus and whole grains. It comes in nine forms (stereoisomers): the same atoms in slightly different shapes. Myo-inositol is the most common in the body and part of the messaging system cells use to respond to hormones, including insulin and follicle-stimulating hormone (FSH).
In the ovary, myo-inositol is the main player. A review of ovarian research describes it as strengthening FSH receptor expression and aromatase, the enzyme that turns androgens into estrogen. That is why myo-inositol is so closely tied to healthy egg development and regular cycles.
What Is D-Chiro Inositol?
D-chiro inositol is a different shape of the same molecule. Your body needs only a little, and it makes that from myo-inositol. Its main job is in insulin signaling.
In the ovary, it acts differently. The same review reports that DCI promotes androgen production in theca cells and turns down aromatase in granulosa cells. In small amounts that is normal. In excess, it may push the ovary the wrong way, and that is the heart of the myo vs. D-chiro debate.
How Your Body Turns One Into the Other
An enzyme called epimerase converts myo-inositol into D-chiro inositol, and its activity is controlled by insulin. More insulin means more conversion, and tissues convert at different rates.
The same review reports that the highest conversion rate is close to 9%, in liver and muscle, which store glucose, and under 2% in heart and brain. It puts the MI:DCI ratio at about 40:1 in plasma and about 100:1 in follicular fluid, the fluid around a developing egg. The ovary wants a lot of myo and very little D-chiro.
The Ovarian Paradox: Why More D-Chiro Isn't Better
With insulin resistance, tissues like muscle and liver respond poorly to insulin and can run low on D-chiro. The ovary, though, appears to stay sensitive to insulin. When insulin runs high, ovarian epimerase keeps converting myo into D-chiro.
The theory is that this leaves the ovary with too much D-chiro and too little myo. The evidence review behind the international PCOS guideline notes that the ovarian MI:DCI ratio is about 100:1 in women without PCOS and about 0.2:1 in women with PCOS. So D-chiro may help insulin-resistant tissues, but piling on more could deepen the imbalance in the ovary. The evidence behind that concern:
- Cell studies. D-chiro reduced aromatase gene expression in a dose-dependent way and raised testosterone in theca cells from women with PCOS, as summarized in the Monastra review.
- Dose matters. An early trial of 44 women with PCOS found ovulation in 19 of 22 women taking 1,200 mg D-chiro a day for 6 to 8 weeks, versus 6 of 22 on placebo. According to the Monastra review, a later study using higher doses could not confirm this and was discontinued.
- Absorption competition. The two forms share a gut transporter. In one study, 1 g of D-chiro significantly reduced absorption of 6 g of myo-inositol, and the plasma ratio was about 6:1, far from the usual 40:1.
Even D-chiro's advocates are careful. An expert group perspective calls 600 to 1,200 mg a day a standard dose, cautions against prolonged high-dose use, and presents 40:1 as a way to get D-chiro's insulin-related benefits without high doses.
Where the 40:1 Inositol Ratio Comes From
40:1 was chosen because it matches healthy plasma: both forms in the proportion the body already uses.
The most-cited test is a trial by Nordio and colleagues comparing seven formulas in 56 women with PCOS: D-chiro alone, and MI:DCI ratios of 1:3.5, 2.5:1, 5:1, 20:1, 40:1 and 80:1. Each group had 8 women, and everyone took 2 g twice a day for 3 months. The authors reported that 40:1 did best at restoring ovulation and normalizing hormone and insulin markers, and that results worsened as the ratio shifted toward D-chiro. An earlier mouse study of 5:1, 20:1, 40:1 and 80:1 pointed the same way. Still, eight women per group is a reason for bigger trials, not a final verdict.
Expert statements back 40:1, including an international experts' opinion that calls myo-inositol, alone or with D-chiro at 40:1, promising. A recent review concluded the combination works at a ratio of "at least 40:1" and that higher ratios, such as 66:1 to 100:1, deserve study.
One caveat: some of these papers list authors with disclosed industry ties. Two authors of the expert group perspective work for a company that sells inositol products, and the first author of the Monastra review previously advised the same company. That does not make the findings wrong, but independent replication matters.
Is 40:1 the best ratio?
It is the best-studied combination and matches normal plasma, but large trials have not proven it beats every alternative. "At least 40:1, never D-chiro-heavy" is a fair summary.
Myo-Inositol Alone vs. 40:1: What the Evidence Shows
What studies in women with PCOS found:
- Myo alone. A meta-analysis of 9 trials (about 500 women) found lower fasting insulin and HOMA-IR, a marker of insulin resistance. Testosterone showed only a non-significant trend, and SHBG rose only in trials of 24 weeks or more.
- Myo alone vs. 40:1, head to head. In a 6-month trial of 50 overweight women, both groups improved metabolic markers. The combination was ahead at 3 months, but there was no significant difference at 6 months.
- 40:1 vs. placebo. In a 6-month trial of 46 women, only the 40:1 group showed significant drops in LH, free testosterone, fasting insulin and HOMA-IR.
- Inositols as a group. A meta-analysis of 10 trials linked inositol to higher ovulation rates than placebo (risk ratio 2.3), and a review of 26 trials and 1,691 women linked it to more regular cycles (risk ratio 1.79).
Now the other side. That same guideline evidence review screened trials for research integrity: 30 trials (2,230 women) were rated low risk and included, while 13 rated moderate risk were left out. Its conclusion: the evidence for inositol in PCOS is "limited and inconclusive." It found myo-inositol likely causes fewer stomach side effects than metformin, while metformin may do more for waist-hip ratio and unwanted hair. The 2023 international guideline states that "inositol (in any form) could be considered in women with PCOS based on individual preferences and values," adds that "specific types, doses or combinations of inositol cannot currently be recommended," and encourages women taking it to tell their health professional.
Bottom line: both have encouraging small studies. The blend may act a bit faster, but no large independent trial shows it beats myo alone.
Myo-Inositol vs. D-Chiro Inositol vs. 40:1: Comparison Table
| Myo-inositol (MI) | D-chiro inositol (DCI) | 40:1 MI + DCI | |
|---|---|---|---|
| What it is | Most common inositol in the body | Made from MI by an insulin-driven enzyme | Both forms in the plasma ratio |
| Main role | Insulin and FSH signaling, egg development, estrogen production | Insulin signaling, mainly in liver and muscle | Supplies both, mostly MI |
| Where it matters most | Ovary and follicular fluid (about 100:1) | Liver and muscle | Matches plasma (about 40:1) |
| Amounts used in studies | 2 to 4 g a day, often split | 600 to 1,200 mg a day when used alone | Up to 4 g a day in total, with DCI at 1/40 of the MI |
| Main caution | Stomach upset at very high doses | High doses may raise androgens and lower estrogen in the ovary; competes with MI for absorption | Same as MI; D-chiro stays small |
| Evidence | Most studied; meta-analyses show metabolic benefits; overall evidence limited | A few small trials, including one positive early RCT; later high-dose work did not confirm it | Small RCTs favor 40:1 over D-chiro-heavy ratios; not proven better than MI alone |
Myo or D-Chiro: Which Should You Consider?
- The 40:1 blend is a sensible default if you want to support healthy insulin signaling and hormone balance: mostly myo, plus a small, plasma-matched amount of D-chiro.
- Myo-inositol alone is a reasonable choice too, especially if ovarian function and egg quality are your focus, or if a D-chiro blend has not agreed with you.
- D-chiro alone, or D-chiro-heavy blends (like 3.6:1 or 1:1), are the ones to approach with care, ideally with a clinician guiding you.
For lifestyle steps that pair well with inositol, see our guides to natural ways to manage PCOS symptoms and lifestyle changes for healthy blood sugar.
How to Read an Inositol Label
- Milligrams per serving, not per capsule. Inositol is bulky, so "2,000 mg" on the front may mean four capsules.
- Capsules or scoops per serving. "Serving Size" tells you how many you take and how long the bottle lasts.
- Do the ratio math. Divide myo by D-chiro: 2,000 mg ÷ 50 mg = 40, so 40:1. A label with 550 mg myo and 150 mg D-chiro works out to about 3.7:1, far more D-chiro-heavy than plasma.
- Your daily total. Many studies used about 4 g of myo a day, such as 2 g twice daily in the Nordio trial. Count how many servings that takes and what it costs per day. Our inositol dosage guide walks through capsules vs. powder.
- Sweeteners and extras. One review notes that sorbitol, maltodextrin and sucralose may reduce myo-inositol absorption, and that add-on vitamins and extras are poorly supported. Simpler is better.
How We Think About It at Ancient Bliss
We formulated our inositol starting from the body's own balance. Myo-inositol is the foundation. D-chiro is a supporting player, and the amount matters more than its presence. That is why we chose 40:1 instead of a D-chiro-heavy ratio, and why our powder contains just the two inositols.
We also encourage patience. In the trials, changes were measured at 3 and 6 months, not 3 weeks. Many people find that splitting a larger daily amount between morning and evening, with food, sits better. And inositol is one part of a plan that includes food, movement, sleep and stress care. For more, read 4 things inositol can do for women's health.
Our Myo and D-Chiro Inositol
When you compare products, look for a clearly stated 40:1 ratio with milligrams of each form listed, around 2,000 mg of myo per serving, no added sugars or sugar alcohols, GMP manufacturing, and a form you will take daily.
Our Myo & D-Chiro Inositol capsules provide 2,000 mg myo-inositol and 50 mg D-chiro inositol (40:1) per 4-capsule serving, with 30 servings per bottle. Prefer to drink it? Our Myo & D-Chiro Inositol Powder delivers the same 2,000 mg + 50 mg in one scoop, dissolves clear, and has no fillers, flow agents, added vitamins or herbs, with 60 servings per container. Both are herbalist-formulated and made in the USA in a GMP facility to support healthy blood sugar metabolism and hormone balance. Ancient Bliss products are third-party tested.
Is Inositol Safe? Side Effects and Cautions
- Side effects. Myo-inositol is generally well tolerated. A safety review found mild nausea, gas and diarrhea only at 12 g a day, far above typical amounts.
- Blood sugar medications. Inositol supports insulin signaling, so talk to your doctor before combining it with metformin, insulin or other glucose-lowering drugs. Never stop or change a prescription on your own.
- Pregnancy, trying to conceive and nursing. Get your provider's okay before you start, especially if you are in a fertility program, since inositol can be one more variable in a carefully timed plan.
- High-dose D-chiro. Avoid large amounts of D-chiro on its own for long stretches unless a clinician is guiding you.
Frequently Asked Questions
What is the main difference between myo-inositol and D-chiro inositol?
They are two shapes of the same molecule. Myo-inositol is the most common form and dominates in the ovary, where it supports FSH signaling and egg development. D-chiro inositol is made from myo by an insulin-controlled enzyme and works mainly in insulin signaling in tissues like liver and muscle.
Why is 40:1 considered the ideal inositol ratio?
It matches the roughly 40:1 balance in healthy blood plasma. A small trial comparing seven ratios found 40:1 worked best for ovulation, and adding more D-chiro made results worse. Larger independent trials are still needed.
Can I take myo-inositol alone instead of a 40:1 blend?
Yes. Myo-inositol alone has the most research. In a head-to-head trial, the 40:1 blend improved metabolic markers faster, but the two were similar by 6 months.
Is it safe to take D-chiro inositol alone?
One early trial of 1,200 mg a day was encouraging, but higher doses raise concerns about the ovary and about blocking myo absorption. Use D-chiro alone only with a clinician's guidance.
How many capsules of 40:1 inositol do I take?
With our capsules, one serving is 4 capsules (2,000 mg myo + 50 mg D-chiro). Many studies used about 4 g of myo a day, which would be 8 capsules or 2 scoops of powder. See our dosage guide for details.
How long does inositol take to work?
Studies usually measured changes after 3 to 6 months, and some markers, like SHBG, only shifted in trials of 24 weeks or longer. Give it a few months of steady use before judging.
Is inositol better than metformin?
Current evidence does not say so. A guideline review found myo-inositol likely causes fewer stomach side effects, while metformin may do more for waist-hip ratio and unwanted hair. Never swap or stop a prescribed medicine without your doctor.
The Bottom Line
Myo-inositol and D-chiro inositol are partners, not rivals. Myo is the foundation; D-chiro helps in small amounts and may cause trouble in large ones. The 40:1 ratio is a well-reasoned way to get both in the balance your body already uses, though the research is early. Read the label, do the ratio math, give it a few months, and keep your care team in the loop. As with any supplement, check with your healthcare provider before starting, especially if you're pregnant, nursing, or take medication.
References
- Monastra G, Vucenik I, Harrath AH, et al. PCOS and Inositols: Controversial Results and Necessary Clarifications. Basic Differences Between D-Chiro and Myo-Inositol. Frontiers in Endocrinology. 2021;12:660381.
- Bizzarri M, Monti N, Piombarolo A, Angeloni A, Verna R. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023;15(8):1875.
- Fitz V, Graca S, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630-1655. doi:10.1210/clinem/dgad762.
- Nestler JE, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine. 1999;340(17):1314-1320.
- Dinicola S, Unfer V, Facchinetti F, et al. d-Chiro-Inositol in Clinical Practice: A Perspective from the Experts Group on Inositol in Basic and Clinical Research (EGOI). Gynecologic and Obstetric Investigation. 2024;89(4):284-294.
- Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences. 2019;23(12):5512-5521. doi:10.26355/eurrev_201906_18223.
- Facchinetti F, Appetecchia M, Aragona C, et al. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opinion on Drug Metabolism & Toxicology. 2020;16(3):255-274.
- Roseff S, Montenegro M. Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. International Journal of Endocrinology. 2020;2020:6461254.
- Lete I, Martínez A, Lasaga I, Centurión E, Vesga A. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecological Endocrinology. 2024;40(1):2301554.
- Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections. 2017;6(8):647-658.
- Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European Review for Medical and Pharmacological Sciences. 2012;16(5):575-581.
- Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. International Journal of Endocrinology. 2016;2016:3204083.
- Pundir J, Psaroudakis D, Savnur P, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG: An International Journal of Obstetrics & Gynaecology. 2018;125(3):299-308.
- Greff D, Juhász AE, Váncsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology. 2023;21:10.
- Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (Recommendations 4.7.1 to 4.7.4 on inositol). Human Reproduction. 2023;38(9):1655-1679.
- Carlomagno G, Unfer V. Inositol safety: clinical evidences. European Review for Medical and Pharmacological Sciences. 2011;15(8):931-936.
